Speaker Profile

Loading

BiographyDr. B Anthony Armson is Professor and Head of the Department of Obstetrics and Gynaecology, Dalhousie University; Senior Physician, Women’s and Newborn Health Program, IWK Health Centre and Central Zone Chief, Obstetrics and Gynaecology, Nova Scotia Health Authority. He is President-Elect, Society of Obstetricians and Gynaecologists (SOGC), Past-President, Association of Academic Professionals of Obstetrics & Gynaecology (APOG) and Past-President of the Canadian Society of Maternal Fetal Medicine (CSMFM).
Dr. Armson received his medical school training at Dalhousie University and worked as a general practitioner in New Brunswick, Canada and Jamaica, West Indies. He completed his residency training in Obstetrics and Gynaecology at the Medical College of Pennsylvania and subspecialty training in Maternal-Fetal Medicine at the Hospital of the University of Pennsylvania in Philadelphia. He joined the academic faculty of the Department of Obstetrics and Gynaecology in 1989 and obtained a Master of Science degree in Community Health and Epidemiology from Dalhousie University in May 2000. He served as Interim Director of the Maternal, Infant and Reproductive Health Research Unit (MIRU), Women’s College Hospital/Sunnybrook Health Sciences Centre in Toronto, from 2006 to 2007.
Dr. Armson is a perinatal clinician investigator who has conducted research in maternal, fetal and neonatal health. His primary research interests are the prediction and prevention of preterm birth, the epidemiology and management of diabetes in pregnancy and the perinatal consequences of maternal obesity. Dr. Armson has been actively involved in multicenter national and international perinatal clinical trials and is collaborator with the Department of Reproductive Health and Research, World Health Organization. He has published over 90 original research papers in peer-reviewed journals. (June 20, 2018)DisclosureI do not have a relationship with a for-profit and/or a not-for-profit organization to disclose.
I do not intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e. “off-label” use of medication).